Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - zanamivir micronized - powder for inhalation - zanamivir micronized 5 mg - zanamivir - zanamivir - zanamivir is indicated for the treatment of both uncomplicated acute illness due to influenza a and b virus in adults and adolescents (> or = 12 years) who have been symptomatic for no more than 48 hours and pediatric patients 7 years and older who have been symptomatic for no more than 36 hours.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - zanamivir micronized - powder for inhalation - zanamivir micronized 5 mg - zanamivir - zanamivir - zanamivir is indicated for the treatment of both uncomplicated acute illness due to influenza a and b virus in adults and adolescents (> or = 12 years) who have been symptomatic for no more than 48 hours and pediatric patients 7 years and older who have been symptomatic for no more than 36 hours.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - zanamivir (unii: l6o3xi777i) (zanamivir - unii:l6o3xi777i) - zanamivir 5 mg - relenza® (zanamivir) inhalation powder is indicated for treatment of uncomplicated acute illness due to influenza a and b virus in adults and pediatric patients 7 years of age and older who have been symptomatic for no more than 2 days. relenza is indicated for prophylaxis of influenza in adults and pediatric patients 5 years of age and older. - relenza is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease (such as asthma or chronic obstructive pulmonary disease) due to risk of serious bronchospasm [see warnings and precautions (5.1)] . relenza is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease (such as asthma or chronic obstructive pulmonary disease) due to risk of serious bronchospasm [see warnings and precautions (5.1)] . - relenza has not been proven effective for treatment of influenza in individuals with underlying airways disease. - relenza has not been proven effective for prophylaxis of i

United States - English - NLM (National Library of Medicine)

dispensing solutions inc. - zanamivir (unii: l6o3xi777i) (zanamivir - unii:l6o3xi777i) - zanamivir 5 mg - relenza® (zanamivir) inhalation powder is indicated for treatment of uncomplicated acute illness due to influenza a and b virus in adults and pediatric patients 7 years of age and older who have been symptomatic for no more than 2 days. relenza is indicated for prophylaxis of influenza in adults and pediatric patients 5 years of age and older. - relenza is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease (such as asthma or chronic obstructive pulmonary disease) due to risk of serious bronchospasm [see warnings and precautions (5.1)] . relenza is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease (such as asthma or chronic obstructive pulmonary disease) due to risk of serious bronchospasm [see warnings and precautions (5.1)] . - relenza has not been proven effective for treatment of influenza in individuals with underlying airways disease. - relenza has not been proven effective for prophylaxis of i

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - zanamivir (unii: l6o3xi777i) (zanamivir - unii:l6o3xi777i) - zanamivir 5 mg - relenza (zanamivir) inhalation powder is indicated for treatment of uncomplicated acute illness due to influenza a and b virus in adults and pediatric patients aged 7 years and older who have been symptomatic for no more than 2 days. relenza is indicated for prophylaxis of influenza in adults and pediatric patients aged 5 years and older. relenza is contraindicated in patients with history of allergic reaction to any ingredient of relenza, including milk proteins [see warnings and precautions (5.2), description (11)] . risk summary available data from published studies suggest that use of relenza during pregnancy is not associated with an increased risk of birth defects or adverse maternal or fetal outcomes. however, these studies are limited by their small sample sizes, which preclude a definitive assessment of the risk (see data). there are risks to the mother and fetus associated with influenza infection in pregnancy (see clinical considerations) . in animal reproduction studies, no adverse developmental

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - zanamivir, quantity: 5 mg - insufflation - excipient ingredients: lactose monohydrate - treatment: relenza (zanamivir) is indicated for the treatment of infections due to influenza a and b viruses in adults and children aged 5 years and older. treatment should commence as soon as possible but no later than forty-eight hours after the onset of the initial symptoms of infection (see precautions). prophylaxis: vaccination remains the primary method of preventing and controlling influenza. relenza is indicated for prophylaxis of influenza a and b in adults and children (5 years and older) to reduce transmission among individuals in households with an infected person. relenza is indicated for prophylaxis of influenza a and b during community outbreaks only in circumstances where such prophylaxis is justified (such as when vaccine that antigenically matches circulating influenza is not available or there is a pandemic). it is not recommended for routine prophylaxis against influenza infection.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - zanamivir - solution for infusion - 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - zanamivir - solution for infusion - 10mg/1ml

European Union - English - EMA (European Medicines Agency)

glaxosmithkline trading services limited - zanamivir - influenza, human - antivirals for systemic use - dectova is indicated for the treatment of complicated and potentially life-threatening influenza a or b virus infection in adult and paediatric patients (aged ≥6 months) when:the patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/orother anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.dectova should be used in accordance with official guidance.

Malta - English - Medicines Authority

glaxo wellcome uk limited - zanamivir - inhalation powder - zanamivir 500 mg - antivirals for systemic use